digital therapeutic
The startup's smartphone-administered digital therapeutic for fibromyalgia received FDA Breakthrough Device designation last year.
KT will also open its digital healthcare platform for NeuroSigma's advanced monitoring and AI analysis services.
Despite the prevalence and associated risks of postpartum depression, a significant portion of mothers never receive a diagnosis or treatment for the condition.
The deal is expected to close this summer, subject to stockholder approval, and will raise $113 million for the combined company.
The platform works to empower patients to be more active in their care journey – and also creates a database of clinical practices and protocols for the psychedelic research community.
The company is also looking to fast-track its opioid use disorder therapy, thanks to relaxed FDA guidelines.
The firms are collaborating to launch a digital medication management and lifestyle platform across Europe.
GSR Ventures led the round with participation from sequoia Capital, Storm Ventures, NextGen Venture Partners and BIXINK Therapeutics.
Oleena's algorithms serve patients personalized guidance on how best to mitigate symptoms, while also monitoring and generating insights for their care team.
While both approaches reduced participants' lower back pain, the company's exercise therapy app was significantly more effective in a direct comparison.